Compare Nomura Holdings Inc (NMR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Nomura Holdings Inc is far larger — about 17.9× Recursion Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NMR | RXRX | |
|---|---|---|
Market Cap | $27.46B | $1.53B |
Sector | Financials | Health |
52-Week High | $10.04 | $6.79 |
52-Week Low | $6.39 | $2.84 |
Dividend Yield | 3.45% | — |
Enterprise Value | — | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
